Immune Checkpoint Inhibitors (PD-1/PD-L1) in Hepatocellular Carcinoma Treatment

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have significantly impacted the treatment landscape for HCC. By blocking the signals that prevent T-cells from attacking cancer cells, these inhibitors enhance the immune system's ability to combat tumors. These therapies have shown potential in improving survival rates, reducing tumor burden, and providing durable responses in patients who previously had few effective options.